We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Treatment for Opioid Use Disorder—Reply

Yngvild Olsen, MD, MPH1; Joshua Sharfstein, MD2
[+] Author Affiliations
1Institutes for Behavior Resources Inc, Baltimore, Maryland
2Maryland Department of Health and Mental Hygiene, Baltimore
JAMA. 2014;312(7):751. doi:10.1001/jama.2014.8432.
Text Size: A A A
Published online


In Reply Dr Stoddard notes that our Viewpoint on the stigma associated with the treatment of opioid use disorder did not discuss naltrexone. In 2010, the US Food and Drug Administration approved the extended-release formulation of naltrexone for relapse prevention of opioid use disorder based on evidence of efficacy against placebo.

The omission in our Viewpoint was intentional. Our goal was to confront the common, inaccurate, and dangerous assertion that long-term therapy with methadone or buprenorphine (both agonist medications) is merely substituting one addiction for another. This misconception inhibits physicians from providing and patients from seeking needed, effective, and compassionate care. As an antagonist medication usually used for less than 6 months, naltrexone does not face the same degree of misunderstanding.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




August 20, 2014
Jeffrey J. Stoddard, MD
1Alkermes Inc, Waltham, Massachusetts
JAMA. 2014;312(7):750-751. doi:10.1001/jama.2014.8429.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...